NVO - Patients Find Weight Loss Drug Zepbound A Game Changer But Makers See Production Delay Until 2025 | Benzinga
The GLP-1 class of drugs for weight loss has gained tremendous popularity but is struggling with a shortage that could extend into 2025. Who says that? The companies that make those drugs predict.
The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S’s (NYSE:NVO) Wegvoy (semaglutide) in 2021. Eli Lilly And Co’s (NYSE:LLY) Zepbound (tirzepatide) appears to spur the momentum after receiving FDA approval in November 2023.
According to the FDA, limited supplies of Eli Lilly’s diabetes drug Mounjaro and weight-loss drug Zepbound are expected through the second quarter of this year due to heightened demand.
NBC’s Christine Romans reports for TODAY on how companies are trying to keep up with demand.
TODAY’s report notes that America’s relationship with weight loss is dramatically transforming as drugs from Eli and Novo Nordisk are changing the game.
Related: Eli Lilly ...